Cynvenio Launches New Cancer Testing Service

Westlake Village-based Cynvenio announced this morning that it has launched a new cancer testing service, the ClearID Total Insight Breast Cancer, to monitor breast cancer patients. According to Cynvenio, the liquid biopsy monitoring service is aimed at patients in treatment and survivors in remission, and is designed to measure immune health status and detect genetic mutations associated with cancer. The company said 12 months of monitoring in the new service costs less than a single DNA sequencing test advertised by other genomic testing companies.